Multiple Myeloma Posts on Medivizor
Navigation Menu

Multiple Myeloma Posts on Medivizor

Evaluating outcomes in patients with multiple myeloma after RVD therapy followed by stem cell transplant outside of clinical trials

Posted by on Oct 13, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the safety and effectiveness of RVD (lenalidomide, bortezomib, dexamethasone) in patients with multiple myeloma before a stem cell transplant (SCT) in a real-life setting (outside of clinical trials). This study concluded that this treatment was safe and effective for these patients. Some background Multiple myeloma...

Read More

Can levels of immune cells predict the outcomes of SCT for patients with multiple myeloma?

Posted by on Oct 9, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study examined if the numbers of different immune cells before and after a stem cell transplant (SCT) predicted treatment outcomes for patients with multiple myeloma (MM). The authors concluded that the numbers of two types of immune cells and antibody levels were associated with a successful transplant. Some background MM...

Read More

Could the addition of daratumumab to standard VTd treatment improve outcomes in multiple myeloma?

Posted by on Oct 6, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study assessed whether the addition of daratumumab (Darzalex) to VTd (bortezomib, thalidomide, dexamethasone) therapy could improve response in patients with multiple myeloma (MM). The authors concluded that the addition of daratumumab improved the outcomes of these patients. Some background Autologous stem cell transplantation...

Read More

Evaluating combination CAR-T cell therapy for recurrent or treatment-resistant multiple myeloma

Posted by on Oct 6, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of combining two T-cell therapies for multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that this treatment showed promising effectiveness for these patients. Some background Treatment for patients with MM that has come back (relapsed)...

Read More

Evaluating a triplet regimen for patients with relapsed or refractory MM after lenalidomide therapy

Posted by on Oct 1, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study examined if PBD (pomalidomide, bortezomib, dexamethasone) was safe and effective in patients with multiple myeloma after lenalidomide (Revlimid) treatment. The authors concluded that pomalidomide improved survival without tumor growth or spread but increased side effects. Some background...

Read More

Looking for patients with relapsed or unresponsive multiple myeloma to try allogeneic CAR-T cell therapy

Posted by on Sep 30, 2019 in Multiple Myeloma | 0 comments

In a nutshell This trial is evaluating the safety and effectiveness of allogeneic CAR-T cell therapy (ALLO-715) in patients with multiple myeloma (MM) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This trial is recruiting in Denver, CO. The details Chimeric...

Read More

Looking for patients with multiple myeloma to try a maintenance therapy combination after SCT

Posted by on Sep 30, 2019 in Multiple Myeloma | 0 comments

In a nutshell This trial will compare the effectiveness of two maintenance therapies in patients with multiple myeloma (MM) after a stem cell transplant (SCT). The main outcome to be measured will be the average time from treatment until death due to any cause.  The details Maintenance therapy is commonly given after SCT to help delay...

Read More

Surviving cancer – is there a greater risk of cardiovascular disease long-term?

Posted by on Sep 16, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors.  They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...

Read More

Evaluating Kd and Vd chemotherapy for patients with relapsed or refractory multiple myeloma

Posted by on Aug 27, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study compared the effectiveness of Kd (carfilzomib, dexamethasone) chemotherapy to Vd (bortezomib, dexamethasone) chemotherapy in patients with multiple myeloma (MM). This study found that Kd improved survival outcomes and had fewer side effects compared to Vd chemotherapy for these patients. Some background Multiple...

Read More

Evaluating the safety and effectiveness of the Shingrix vaccine for patients with blood cancers

Posted by on Aug 23, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of the herpes zoster vaccine (Shingrix) in patients with blood cancer who are receiving anti-cancer therapy. This study concluded that the Shingrix vaccine was effective in these patients, with manageable side effects. Some background Shingles is caused by a virus called herpes zoster....

Read More

Looking for patients with relapsed or unresponsive multiple myeloma to test a new antibody drug

Posted by on Aug 14, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study is examining the effectiveness of antibody drug tiragolumab with or without standard treatment for relapsed or unresponsive multiple myeloma or non-Hodgkin lymphoma. The main outcome would be the side effects experienced by patients 1 year after treatment.  The details Both multiple myeloma (MM) and non-Hodkin lymphoma...

Read More